Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey

被引:107
作者
Karanges, Emily A. [1 ,2 ]
Suraev, Anastasia [1 ,2 ]
Elias, Natalie [1 ,2 ]
Manocha, Ramesh [3 ]
McGregor, Iain S. [1 ,2 ]
机构
[1] Univ Sydney, Lambert Initiat Cannabinoid Therapeut, Sydney, NSW, Australia
[2] Univ Sydney, Sch Psychol, Sydney, NSW, Australia
[3] HealthEd, Sydney, NSW, Australia
来源
BMJ OPEN | 2018年 / 8卷 / 07期
关键词
primary healthcare; medicinal cannabis; therapeutics; attitude; MEDICAL MARIJUANA; RESPONSE RATES; PHYSICIANS;
D O I
10.1136/bmjopen-2018-022101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To examine the knowledge and attitudes of Australian general practitioners (GP) towards medicinal cannabis, including patient demand, GP perceptions of therapeutic effects and potential harms, perceived knowledge and willingness to prescribe. Design, setting and participants A cross-sectional survey completed by 640 GPs (response rate=37%) attending multiple-topic educational seminars in five major Australian cities between August and November 2017. Main outcome measures Number of patients enquiring about medicinal cannabis, perceived knowledge of GPs, conditions where GPs perceived it to be beneficial, willingness to prescribe, preferred models of access, perceived adverse effects and safety relative to other prescription drugs. Results The majority of GPs (61.5%) reported one or more patient enquiries about medicinal cannabis in the last three months. Most felt that their own knowledge was inadequate and only 28.8% felt comfortable discussing medicinal cannabis with patients. Over half (56.5%) supported availability on prescription, with the preferred access model involving trained GPs prescribing independently of specialists. Support for use of medicinal cannabis was condition-specific, with strong support for use in cancer pain, palliative care and epilepsy, and much lower support for use in depression and anxiety. Conclusions The majority of GPs are supportive or neutral with regards to medicinal cannabis use. Our results highlight the need for improved training of GPs around medicinal cannabis, and the discrepancy between GP-preferred models of access and the current specialist-led models.
引用
收藏
页数:9
相关论文
共 30 条
[1]  
Adler J.N., 2013, New England Journal of Medicine, V368, P866, DOI DOI 10.1056/NEJMCIDE1305159
[2]  
[Anonymous], RACGP POS STAT MED U
[3]  
[Anonymous], 2017, HLTH EFF CANN CANN C
[4]  
[Anonymous], ALC OTH DRUG TREATM
[5]  
[Anonymous], 2017, Drug Statistics Series
[6]  
Australian and New Zealand College of Anaesthetists (ANZCA), 2015, STAT MED CANN PART R
[7]  
Australian and New Zealand College of Anaesthetists (ANZCA), 2016, VICT ANZCA B
[8]  
Bartone T, 2017, MED CANNABIS STILL L
[9]  
Bonevski B, 2011, AUST FAM PHYSICIAN, V40, P427
[10]   Medicinal Cannabis: A Survey Among Health Care Providers in Washington State [J].
Carlini, Beatriz H. ;
Garrett, Sharon B. ;
Carter, Gregory T. .
AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2017, 34 (01) :85-91